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Introduction
Alzheimer’s disease was first identified by Alois Alzheimer in 
1906. However not until the 1970’s did it become a major and 
significant area of research. Since that time much has been 
discovered about the mechanisms of the disease, however the 
precise biological processes in the disease are mostly unknown 
and the large variance in its progression amongst patients with 
the disease needs to be better understood. 
Alzheimer’s disease is a neurodegenerative disease that effects 
memory, behavior and eventually leads to death within an aver-
age of 8 years of diagnosis, the last three of which are typically 
spent with full time care or in an institution. 
The changing demographics worldwide and with the baby boom 
generation reaching ages 70 and beyond has led Alzheimer’s 
disease to become one of the biggest healthcare concerns in 
the developed world. This greater prevalence and incidence of 
Alzheimer’s disease, the largest cause of dementia, has created a 
huge burden on society. 
Millions of Americans have Alzheimer’s disease and other forms 
of dementias. An estimated 5.4 million Americans of all ages had 
Alzheimer’s disease in 2016. One in nine people aged 65 years 
or older and about one third (32%) of people aged 85 and older 
have the disease (Herbert et al., 2013). 
The future projections for Alzheimer’s disease are equally bleak. 
Approximately 476,000 people will develop the disease in the 
United States in 2016, with the numbers increasing dramatically 
with age. There will be 63,000 new cases among people aged 65 
to 74 and 241,000 new cases among people aged 85 and older. 
Because of the ageing demographics in the United States, these 
numbers are projected to double by 2050 (Herbert et al., 2001). 
Alzheimer’s disease is one of the leading causes of both mortal-
ity and morbidity in the United States. It is currently the sixth 
leading cause of death for those 65 years and older. According 
to data from the National Center for Health Statistics of the 
Centers for Disease Control and Prevention (CDC), 84,767 
people died from it in 2013. These numbers only consider 
those who have cause of death listed as Alzheimer’s disease on 
their death certificate. Death certificates for individuals with 
Alzheimer’s disease often list other acute conditions, such as 
pneumonia, as the primary cause of death and therefore death 
due to Alzheimer’s is most likely underreported. 
The cost of the disease is very substantial, both in terms of the 
value of the unpaid caregiving for Alzheimer’s disease which has 
been estimated at $221.3 billion in 2013, and the total payments 
made which in 2016 was estimated at $236 billion. Overall the 
cost of healthcare, long term care and hospice care for indi-
viduals with the disease makes it one of the costliest chronic 
diseases to society (Hurd et al., 2013). 
Alzheimer’s disease is characterized by a gradually worsening 
ability to remember new information. This occurs because the 
first neurons to be damaged and destroyed are in the area of 
the brain responsible for creating new memories. As the disease 
causes the destruction of neurons in other regions of the brain, 
symptoms worsen and individuals experience other difficulties 
such as challenges in problem solving and planning, confusion 
with time and place, decreased and poor judgement, and with-
drawal from social activities and work. 
There are about 100 billion neurons in the adult healthy brain. 
During the development of Alzheimer’s disease, the connec-
tions and synapses between neurons is hindered and the overall 
number of neurons decrease. The destruction of neurons and 
the disruption of the cellular neuronal circuits lead to many of 
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the symptoms. The brains of people with advanced Alzheimer’s 
disease show inflammation, dramatic shrinkage from cell loss 
and widespread debris from dead and destroyed neurons. Some 
of these brain changes can begin 20 years prior to the onset of 
symptoms for the disease (Villemagne et al., 2013). 
No simple test currently exists for diagnosis of Alzheimer’s dis-
ease, rather an individual’s physician together with the help of a 
neurologist will use a variety of methods to assist in a diagnosis. 
These include obtaining a family history and medical history of 
the patient which may include psychiatric, cognitive and behav-
ioral histories. In addition, diagnosis is often aided by conducting 
cognitive tests and physical and neurological examinations. Finally, 
a physician will typically use blood tests and brain imaging to rule 
out other possible causes of behavioral and memory changes 
such as tumor formation or nutrient deficiencies. 
Much research has focused on a potential precursor to 
Alzheimer’s disease known as Mild Cognitive Impairment (MCI). 
An individual with Mild Cognitive Impairment will experience 
mild but measurable changes in thinking abilities that are no-
ticeable to friends and families of the affected person but that 
do not affect the person’s ability to carry out normal everyday 
functions and activities (Roberts & Knopman, 2013). It is esti-
mated that about 20% of people over the age of 65 have Mild 
Cognitive Impairment. Recent studies have shown that an aver-
age of 32% of people with MCI will develop Alzheimer’s disease 
within 5 years. However, some with MCI will see their cognitive 
decline stabilize, and in some cases, they may even return to 
normal cognition (Ward et al., 2013). 
In a small percent of those diagnosed with Alzheimer’s disease 
the development of the disease can be attributed to genetic 
mutations. Three genes have been implicated in its development. 
These are the genes which encode for the amyloid precursor 
protein (APP),  the genes for presenilin-1 and for presenilin-2. 
Mutations in both the APP gene and the presenilin-1 gene result 
in guaranteed development of the disease, while a mutation in 
the presenilin-2 gene leads to a 95% chance of its development. 
Individuals with mutations in any of these three genes will usual-
ly develop symptoms as young as age 30, unlike the vast majority 
of Alzheimer’s cases, which are late onset where symptoms typi-
cally develop at age 65 and over (Bekris et al., 2010). 
People with Down syndrome are born with an additional copy 
of chromosome 21 and have a greater risk of developing all 
forms of dementia including Alzheimer’s disease. Studies have 
found that more than 75% of people with Down Syndrome 
aged 65 and over have Alzheimer’s. While the exact relationship 
between Down Syndrome and Alzheimer’s is not entirely clear, 
one possible explanation might be that the gene that codes for 
amyloid precursor protein is located on chromosome 21 and 
the additional copy of this gene increases the likelihood of the 
development of the plaques associated with the amyloid precur-
sor protein. By age 40 most people with Down Syndrome have 
high levels of beta amyloid plaques in their brains, a marker for 
Alzheimer’s disease (Lott & Dierssen, 2010). 
Besides for the genetic factors in Alzheimer’s disease much re-
search has been conducted on the effects of environmental and 
modifiable risk factors. Studies have shown that regular physical 
activity, and management of cardiovascular risk factors such as 
obesity, smoking and high blood pressure reduce the risk of the 
development of Alzheimer’s disease and dementia. There is also 
evidence that a healthy lifestyle and diet as well as continued 
engagement in learning can prevent cognitive decline in old age 
(Baumgart et al., 2015). 
Current treatment options for Alzheimer’s disease are limited. 
None of the pharmacological treatments available cures or 
stops the damage the disease causes to the brain. The six drugs 
that have thus far been approved by the U.S Food and Drug 
Administration (FDA) focus primarily on increasing the levels 
of neurotransmitter present in the brain. While this helps deal 
with the symptoms of Alzheimer’s disease such as memory loss 
and reduced cognitive capacity, these drugs don’t deal with the 
underlying issues in the disease, and their effectiveness is limited 
to the early stages of the disease. 
This paper attempts to review some of the complex molecular 
mechanisms involved in Alzheimer’s disease. It will explore the 
current research on the molecular mechanisms in Alzheimer’s 
disease to better understand the development of the disease 
and the wide variance in disease progression, and explain possi-
ble areas of future research in the development of more effec-
tive therapeutic agents. 
Methods
This study was performed through the analysis of various origi-
nal and peer reviewed articles which were accessed using data-
bases such as the Touro Database, PubMed, and Google Scholar. 
The research collected in this study was used to understand the 
molecular processes in Alzheimer’s disease, and to evaluate the 
various hypotheses postulated in the formation of the disease. 
Discussion
Since the systematic biochemical analysis of patients with 
Alzheimer’s began in the early 1970’s much knowledge has been 
acquired concerning the possible mechanisms responsible for 
the disease. The earliest research into neurochemical abnormal-
ities that are present in Alzheimer’s disease led to the formula-
tion of the cholinergic hypothesis.
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Cholinergic Hypothesis
Acetylcholine was the first neurotransmitter to be identified 
and is the neurotransmitter used in all cholinergic neurons. It is 
fundamental in both the central nervous system (CNS) and the 
peripheral nervous system (PNS). 
Successful neurotransmission of acetylcholine is dependent on 
proteins needed for its synthesis, transport, degradation and re-
uptake. Acetylcholine synthesis takes place in the cytoplasm of 
cholinergic cells. The enzyme, choline acetyltransferase (ChAT) 
catalyzes the combination reaction of dietary choline and Acetyl-
CoA, generated by the mitochondria, to form the product ace-
tylcholine. Three forms of the ChAT enzyme have been found in 
humans. Formation of acetylcholine is followed by its transfer to 
the synaptic vesicles before release. This step is enabled by the ve-
sicular acetylcholine transporter (VAChT). When the cholinergic 
neurons are depolarized, acetylcholine is released by exocytosis 
into the synaptic cleft. On the post synaptic neuron, acetylcholine 
can activate both muscarinic and nicotinic receptors. Nicotinic 
ACh receptors are ion gated channels which are selective for 
cations including sodium, potassium, and calcium. Nicotinic recep-
tors are made up from a combination of five different subunits. 
The large variance in the properties and functions of the different 
nicotinic receptors is a direct result of the many different possible 
combinations of subunits that form each receptor. In the PNS the 
activation of these receptors results in the transmission of the 
signal to ganglion cells and the innervation of muscles and glands. 
In the CNS the role of nicotinic receptors is regulatory rather 
than purely the transmission of excitatory or inhibitory signals. 
In the PNS the nicotinic receptors are mostly located on the 
post synaptic neuronal membrane, where they are activated by 
acetylcholine and facilitate the transmission of signals. However, 
in the CNS the receptors are mostly located on the pre-synaptic 
neuronal membrane where their activation regulates the release 
of acetylcholine and other neurotransmitters into the synapse. 
The activation of these receptors results in an increase in calcium 
levels in the presynaptic neuron, which is a crucial step in the 
exocytosis of neurotransmitters such as GABA, glutamate, do-
pamine and serotonin into the synapse. Muscarinic receptors are 
G-protein coupled receptors, and unlike the nicotinic receptors, 
their role is largely in the transmission of signals. Five isoforms of 
the receptor have so far been identified. M1, M3 and M5 are ex-
citatory receptors and their activation results in the formation of 
second messengers by phospholipase C which results in closure 
of K+ channels enabling the greater depolarization of the cell 
and the transmission of signal down the axon.  M2 and M4 are 
inhibitory and their activation has the opposite effect. They result 
in the inhibition of adenylyl cyclase which leads to lower levels 
of cyclic adenosine monophosphate (cAMP) and promotes the 
inhibition of [Ca]++ channels diminishing cell excitability. 
In the synaptic cleft acetylcholine is broken down to its com-
ponents Acetyl-CoA and choline by the enzyme acetylcholin-
esterase (AChE). AChE is one of the most kinetically effective 
enzymes. It is able to catalyze the breakdown of 5000 molecules 
of acetylcholine per second. The choline transporter, CHT1, fa-
cilitates the uptake of choline, that is produced by the break-
down of acetylcholine by AChE, into the presynaptic neuron. 
This transporter is also the source of the choline used in ace-
tylcholine synthesis and it therefore plays a crucial role in the 
recycling of acetylcholine (Fig. 1, Ferreira Vieira et al., 2016). 
Early research into Alzheimer’s disease showed reduced activ-
ity of choline acetyltransferase in the amygdala, hippocampus 
and cortex of patients with the disease. In one such study, the 
levels of the enzyme responsible for acetylcholine synthesis in 
patients with the disease was found to be lower than 10% of the 
normal activity seen in the control group. Similarly, the levels of 
acetylcholinesterase in the same brain regions were markedly 
lower in patients with Alzheimer’s disease (Davies & Maloney 
1976).
Further studies showed that in addition to the decreased activ-
ity of the enzymes responsible for acetylcholine synthesis, the 
levels of acetylcholine uptake by neurons in the frontal cortex 
and in the hippocampus, were significantly lower in patients 
with Alzheimer’s disease. In the frontal cortex, the transport 
of choline into synaptosomes was reduced by 50% and an even 
greater reduction of 80% was seen in the hippocampus. Further 
evidence of the loss of cholinergic function in the uptake of 
Figure 1 Schematic representation of biological aspects involving 
acetylcholine neurotransmission  (Ferreira Vieira et al , 2016)
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choline in Alzheimer’s disease is seen in the lower densities of 
the presynaptic high affinity choline uptake carrier (HACU) in 
both the cortex and hippocampus (Rylett et al., 1983; Pascual 
et al., 1991). 
Other studies have shown there to be a reduction in the num-
ber of nicotinic and muscarinic M2 acetylcholine receptors in 
Alzheimer’s disease brains and there is evidence for the dis-
ruption of the M1 receptors and their G-proteins which ef-
fects the second messenger systems and transmission of signals 
(Whitehouse et al., 1988).
The cholinergic hypothesis of Alzheimer’s disease was also evi-
denced by the reduction in the amount of acetylcholine released 
from neurons in the brains of affected patients. An experiment 
conducted on brain tissue of both controls and patients with 
the disease collected with short post mortem delay, showed 
a significant reduction in tritium (3H-acetylcholine) release 
during potassium stimulation, as compared with the controls 
(Nilsson et al., 1986). 
In addition, the loss of cholinergic neurons as a result of the 
neurodegeneration caused by Alzheimer’s has further impli-
cated the cholinergic system in the etiology of the disease. In 
particular, the selective degeneration of neurons in the nucleus 
basalis of Meynert, a significant source of neurons which are 
fundamental in the cholinergic innervation of the cerebral 
cortex, explains the reduction in the levels of acetylcholine in 
individuals with Alzheimer’s disease (Whitehouse et al., 1982).
It has also been demonstrated that the cholinergic system plays 
a role in memory and in learning. The loss of the neurons in 
the nucleus basalis of Meynert has been correlated with the 
impaired memory and cognitive abilities seen in patients with 
Alzheimer’s disease. The effects on the cholinergic system has 
also been shown to result in the many behavioral and psycho-
logical symptoms seen in individuals with the disease. Emotional 
processing deficits associated with Alzheimer’s disease may 
be caused by loss of cholinergic function in the areas of the 
amygdala and frontal cortex. Apathy and depression as well as 
disturbance in sleep cycle are symptoms commonly found in 
patients with Alzheimer’s disease. It has been postulated that 
the degeneration of cholinergic neurons and the resulting loss 
of regulation of neurotransmitters, including dopamine and se-
rotonin, is responsible for the many psychiatric symptoms ob-
served. Moreover, cholinesterase inhibitors, the primary focus 
of the current pharmacologic agents available for the treatment 
of Alzheimer’s disease have shown to improve many of the psy-
chiatric symptoms. Clinical trials conducted on affected patients, 
reported reduced delusions, stress, apathy and depression in the 
treated group (Ferreira et al., 2016; Pinto et al., 2011). 
There is much research that shows the link between the cholin-
ergic system and Alzheimer’s disease. The neurodegeneration of 
neuronal cells critical in the cholinergic system, the reduction in 
the enzymes responsible for the synthesis of acetylcholine, and 
lower levels of proteins that facilitate choline uptake in neuro-
nal cells that is seen in the brains of patients with Alzheimer’s 
disease, together with the role that the cholinergic system plays 
in memory and learning have contributed to the formulation of 
the cholinergic hypothesis. However there remains some incon-
sistencies in this hypothesis that suggest the role of the cholin-
ergic system in the disease needs to be better understood. 
Although cholinergic loss seems to correlate with cognitive 
impairment, other factors such as loss of synapses and pyra-
midal cells may also be responsible for the cognitive decline. 
Additionally, some patients with Alzheimer’s disease do not 
show the large decreases in ChAT activity that would be ex-
pected. Moreover, patients with inherited olivopontocerebellar 
activity have levels of ChAT which are reduced to similar levels 
as those seen in Alzheimer’s patients yet they don’t experience 
the decline in cognition and memory that would be expected. 
An expectation of the cholinergic hypothesis would be that 
drugs that restore cholinergic function to the brain regions ef-
fected by Alzheimer’s disease would improve and reverse the 
cognitive symptoms seen in the disease. Five drugs have been 
approved by the FDA for Alzheimer’s disease. Four of these 
drugs are cholinesterase inhibitors and one is a receptor antag-
onist. The cholinesterase inhibitors have shown limited success 
in clinical trials and are mostly able to merely delay the progres-
sion of the disease. The failure of the cholinesterase inhibitors 
to cure Alzheimer’s disease was seen by some as the strongest 
evidence against the cholinergic hypothesis. 
Many researchers have continued to explore the role of neu-
rotransmission in the disease because of the acetylcholine 
dysfunction seen in the brains of Alzheimer’s disease patients. 
However, the inconsistencies with the cholinergic hypothesis 
have resulted in a shift in the focus of much of the more re-
cent research towards two of the hallmarks of the disease, the 
buildup of beta amyloid plaques in the extracellular space, and 
the intracellular formation of neurofibrillary tangles (Craig et al., 
2011; Francis et al., 1999).
Amyloid Cascade Hypothsis
The origins of the Amyloid Cascade Hypothesis lie in the se-
quencing of the Aβ extracted from cerebral blood vessels 
and the brain parenchyma of Alzheimer’s disease patients. The 
identification of the Aβ sequence led to the sequencing of the 
amyloid precursor protein gene (APP). This gene located on 
chromosome 21 encodes the holoprotein that is cleaved first by 
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the β-amyloid cleaving enzyme and then by γ-secretase to form 
the Aβ peptide. (Masters et al., 1985; Kang et al., 1987; Hussain 
et al., 1999).  The essence of the amyloid cascade hypothesis is 
that the increased production or decreased clearance of the 
Aβ peptides causes the disease. Aggregation of the hydrophobic 
Aβ40 and Aβ42 peptides results in the formation of insoluble 
plaque which triggers a cascade of changes ultimately resulting 
in cell death and the symptoms of the disease. 
Human APP belongs to a family of type I transmembrane gly-
coproteins that also includes the similar amyloid precursor like 
proteins 1 and 2 (APLP1 and APLP2). These proteins are func-
tionally the same as the APP but they lack the Aβ sequence. The 
APP gene is highly conserved and several alternatively spliced 
isoforms of APP have been identified in humans. Invertebrates 
such as the fruit fly D. melanogaster and the worm C. elegans 
contain paralogs of the amyloid precursor protein, amyloid pro-
tein precursor-like (APPL) and APP-like 1, (APL-1). The zebraf-
ish genome encodes two variants of APP, Appa and Appb. All of 
these proteins share domains that are highly conserved in both 
the large extracellular domains and in the shorter cytoplasmic 
domain (Nicolas & Hassan, 2014). 
APP can undergo two types of processing depending on the 
secretases that cleave it. In the non-amyloidogenic pathway APP 
is cleaved within the Aβ sequence by α-secretase forming the 
sAPPα extracellular protein and the membrane bound αAPP-
CT. The membrane bound protein is then cleaved by γ-secretase 
forming P3 peptide and amyloid precursor protein intracellular 
domain (AICD). 
In the amyloidogenic pathway, APP is first cleaved by β-secretase 
forming the soluble sAPPβ protein and the C-terminal mem-
brane bound fragment βAPP-CTF. The subsequent cleavage of 
the βAPP-CTF fragment by γ-secretase forms the Aβ peptide 
and the amyloid precursor intracellular domain (ACID). The 
release of the Aβ peptide by γ-secretase is thought to be fun-
damental to Alzheimer’s disease pathology, and the aggregation 
of these insoluble and toxic protein fragments results in the for-
mation of the senile plaque that is a hallmark of the disease.  In 
the earliest and most direct elucidation of the amyloid cascade 
hypothesis the aggregation of the Aβ peptide was explained as 
critical event in the development of Alzheimer’s disease. The 
accumulation of the peptide was seen as both a cause of cell 
death and as a crucial step in the hyper-phosphorylation of Tau 
proteins leading to the formation of intracellular neurofibrillary 
tangles (Hardy & Higgins, 1992).
Critical evidence for the ACH comes from human genetics. The 
observation that the Aβ peptide deposited in elderly Down’s 
syndrome patients, was the same as that found in patients with 
Alzheimer’s suggested that a gene on chromosome 21 was 
central to the development of the disease (Glenner & Wong, 
1984a). Later studies on a family with a history of early onset 
Alzheimer’s provided further evidence for a genetic link in the 
disease, and was the basis for much of the research that fol-
lowed. These studies revealed a missense mutation in the APP 
gene that resulted in a V717I amino acid substitution in the 
protein product. The position of the substitution, just upstream 
from the carboxyl terminal cleavage site of the Aβ peptide, pro-
vided further evidence for the role of Aβ peptide in the etiology 
of the disease (Goate et al., 1991). 
The link between mutations in the presenilin 1 and presenilin 2 
genes, that encode a part of the γ-secretase mutiprotein com-
plex, and the development of the disease has likewise provided 
support for the amyloid cascade hypothesis.
There are now hundreds of mutations to the PSEN-1, PSEN-2 
and APP genes that are known to cause early onset familial AD 
(FAD). These mutations effect the formation and accumulation of 
amyloid plaque in several ways. Some of these mutations result in 
Figure 2 The domain structure of APP family members in model 
organisms  All APP homologs contain the extracellular domains E2, an 
acidic domain (Ac), a copper binding domain (CuBD), and a heparin 
binding domain (HBD)  A kunitz protease inhibitor domain (KPI) is 
found only in the APP and APLP-2 forms of the protein and the Aβ 
sequence is only present in APP  The most highly conserved domain 
across species is the intracellular YENPTY domain (Nicolas & Hassan, 
2014) 
Figure 3 proteolytic processing of APP (Nicolas & Hassan, 2014) 
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the extension of the C-terminal side of the Aβ peptide, others in-
crease the overall ratio of the longer less soluble Aβ peptides to 
the shorter more soluble forms, and some are directly responsi-
ble for an increase in the aggregatory properties of the protein. 
In addition to the effects of these three genes on familial 
Alzheimer’s disease, there are also genes that are connected 
to sporadic Alzheimer’s disease (SAD). There are three major 
alleles of the APOE gene in the human population (Nickerson et 
al., 2000). These are APOE2, APOE3 and APOE4. A heterozygous 
APOE4 carrier has a four-fold increased risk for the disease 
as compared with the homozygous APOE3 genotype. The ho-
mozygous APOE4 genotype has an even more drastic 12 fold 
increase in risk. Conversely, a carrier of the APOE2 gene has 
a reduced risk of the disease (Verghase et al., 2011). The ApoE 
protein is believed to have a role in the deposition of the am-
yloid plaques. Furthermore, there are specific mutations in the 
APP gene that result in the protection against Alzheimer’s dis-
ease, with the evidence suggesting that they disrupt the ability 
to form the Aβ peptides. 
While many of the above studies have shown a link between the 
genes involved in the formation of the Aβ peptides and the de-
velopment of the disease, like the cholinergic hypothesis there 
remain some inconsistencies and unanswered questions. These 
questions have led many to believe that rather than being the 
central mechanism in the development of Alzheimer’s disease, 
the formation of amyloid plaque may just be one of several fac-
tors that contribute to its development. 
Much to the frustration of the proponents of the ACH, the amy-
loidocentric drugs have failed to produce the results that would 
have been expected according to the hypothesis. The phase three 
clinical trials of 6 of these drugs have provided disappointing 
results. Triampirosate, a small molecule drug that prevents the 
aggregation of Aβ peptide showed no significant effect on cogni-
tion and memory during the clinical trials. Similarly no significant 
effect on primary outcomes were seen in the trials of Tarenflurbil, 
a γ-secretase modulator that reduces the ratio of aggregatory 
Aβ peptide to the shorter more soluble form. The only limited 
success in this class of drug for the treatment of Alzheimer’s dis-
ease, was Solanezumab, a monoclonal antibody directed at the 
amyloid plaque protein. In its phase three clinical trials there was 
a significant improvement in cognitive abilities. In an extension 
trial, these positive effects on cognition were sustained over a 
two-year period raising hope and providing some evidence for a 
disease modifying effect (Karran & De Strooper, 2016). 
A central tenet of the amyloid cascade hypothesis is that the 
accumulation of the Aβ peptides causes both cell death and 
the intracellular neurofibrillary tangles. Tissue studies in vitro 
have shown the toxic nature of Aβ peptide and Aβ42. Many 
early studies showed that the addition of the peptide to cell 
culture resulted in neuronal death and apoptosis as well as 
synaptic and dendritic loss. In vivo studies produced similar 
results, when these deleterious effects were seen in mouse 
brains injected with the peptide. However, the relationship 
between the formation of amyloid plaque and the tangles re-
mains unclear. The aggregation of plaque initially takes place 
in the frontal cortex, before spreading throughout the cortex 
as the disease progresses. Neurofibrillary tangles first appear 
in the limbic system, in the hippocampus and dentate gyrus. 
This spatial discrepancy together with further studies that 
have shown that the tangles appear before the accumulation 
of plaque, and are more closely correlated with disease pro-
gression and severity have contributed to the re-evaluation of 
the ACH (Braak & Braak, 1998). 
An analysis conducted to determine the correlation between 
cognitive abilities and some of the neurochemical and struc-
tural measurements in 15 patients with Alzheimer’s disease 
further questions the relationship between amyloid plaque 
and cognitive impairment. In this study, there were only weak 
correlations between plaque and tangles and performance 
on psychometric tests. In contrast, the density of the cortical 
synapses was found to be strongly correlated with the psycho-
logical assessments of the patients (Terry et al., 1991). Mouse 
models of Alzheimer’s disease have shown the accumulation 
of plaques without the observed cognitive impairments. In 
addition, neuroimaging analysis have shown the presence of 
plaques in cognitively healthy people. 
The amyloid cascade hypothesis dominates the field of 
Alzheimer’s research as the most complete and evidenced 
hypothesis about the causes of the disease. However, it is not 
without its flaws, which has led to some reassessing the hy-
pothesis and to others dismissing its significance altogether. 
The genetic link to Alzheimer’s disease was considered the cen-
tral evidence for this hypothesis. Mutations in APP, PSEN1 and 
Figure 4 Amyloid precursor proteins  The diagram shows both the 
β- secretase and γ-secretase cleavage sites and protective and 
pathogenic mutations (Karran & De Strooper, 2016) 
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PSEN2 are associated with familial Alzheimer’s disease and the 
EPOE4 allele is a risk factor for sporadic AD. The fact that these 
genes are involved in the processing of APP and the formation 
of Aβ peptide has provided strong evidence for the role of am-
yloid plaque in disease progression. The mutations associated 
with APP are all located in the proximity of the cleavage sites of 
Aβ peptide, suggesting that the plaque formed by the peptide is 
central to the development of the disease. However, the muta-
tions in the presenilin genes, which encode γ-secretase, occur 
throughout the protein, and not just the sites that are involved 
with Aβ formation. This has led to the belief that defective APP 
processing may in fact be the actual cause of the disease, and 
that the formation of the Aβ peptide and plaques might just be 
a secondary effect. This belief is supported by the weak correla-
tion between plaque formation and density and cognition. While 
the ACH is the best defined and most widely accepted view, the 
data both for and against this hypothesis is significant. Many still 
strongly support the ACH and others have dismissed it entirely 
to focus on other hypotheses. 
Alternative Hypotheses
Analysis of the relationship between mitochondrial function 
and Alzheimer’s disease has resulted in the proposition of 
the mitochondrial cascade hypothesis (MCH). The funda-
mental principle of the MCH is that Alzheimer’s disease is 
a usual if not inevitable consequence of ageing. Support for 
this hypothesis comes from the undoubted evidence of mi-
tochondrial damage in the brains of patients with the dis-
ease. Mitochondria are critical in the regulation of cell death 
and mutations in mitochondrial DNA and oxidative stress 
both contribute to ageing and neurodegenerative diseases 
(Lin & Beal, 2006). Studies using flourodeoxyglucose positron 
emission tomography (PET) imaging, as a measure of oxygen 
uptake, showed deficits in the brains of Alzheimer’s disease 
patients (Jack et al., 2012). There is also strong evidence of 
free radical damage in AD brains (Sonnen et al., 2008). These 
findings suggest that dysfunctional and altered mitochondria 
is central in the disease. Experimental evidence for the MCH 
comes from studies conducted on cybrid cells- cells that 
contains mitochondria from a different cell. Studies on cy-
brid cells which were induced to take up mitochondrial DNA 
from platelets of patients with Alzheimer’s disease, showed 
increased production of beta amyloid peptide (Khan et al., 
2000). This data provides support for the MCH, by show-
ing that mitochondrial deficiency is the cause of the amyloid 
plaques and central to disease development. Despite this 
data, the MCH fails to explain the full array of Alzheimer’s dis-
ease pathology. In addition, genome wide association studies 
have failed to show links between mitochondrial genes and 
proteins and the disease. The cybrid experiments show that 
mitochondrial dysregulation in Alzheimer’s disease leads to 
increases in beta amyloid production. However, they do not 
account for the mutations in APP and PSEN which increase 
the ratio of insoluble Aβ peptide to the smaller soluble form, 
or the mutations that result in an increase in aggregatory 
properties. 
Another hypothesis that deserves mention is the metabolism 
hypothesis. According to this hypothesis, the underlying cause 
of AD is hypometabolism of glucose in the brain. The basis of 
this hypothesis was experiments on a rat model injected with 
streptozotocin, which effects insulin production, and resulted 
in decreased glucose metabolism in the brain, and learning 
and memory impairments (Lannert & Hoyer 1998). Further 
studies showed that the insulin signaling pathway is signifi-
cantly depressed in many brain regions in Alzheimer’s disease 
(Steen et al., 2005). Clinical experiments also have linked 
insulin with Aβ peptide buildup. Incretin mimetics injected 
in mice resulted in significant reductions in Aβ plaque load 
(Mcclean & Hölscher, 2014), and there is also data that sug-
gests that Aβ oligomers disrupt the insulin pathway leading 
to an increase in glycogen synthase kinase 3β (GSK 3β), a Tau 
kinase, and the formation of neurofibrillary tangles (Morgen 
& Frölich, 2015). As with the mitochondrial hypothesis, no 
data from genome wide association studies have confirmed 
this link between Alzheimer’s disease and insulin signaling. 
However, this hypothesis does provide several targets for 
possible therapeutic intervention.
A more generalized proposition is the cell cycle re-entry 
hypothesis. This view examines Alzheimer’s disease from 
the perspective of age related DNA damage. Neurons are 
post mitotic and therefore must maintain integrity long 
term. Brain cells have a very high energy requirement and 
therefore are particularly susceptible to DNA damage. 
Mitogen kinases have increased expression in the brains 
of Alzheimer’s disease patients, and have been posited to 
stimulate the neurodegenerative pathways and effect cell 
repair mechanisms (Arendt et al., 1995). Later studies on 
differentiated neurons that were infected with the on-
cogenes, c-myc and ras resulted in DNA duplication and 
hyperphosphorylated and unusually folded Tau proteins, 
similar to those observed in Alzheimer’s disease. However, 
the disrupted DNA repair mechanisms does not adequately 
explain the formation of Aβ plaques, and as before there is 
little support for this hypothesis from genome wide asso-
ciation studies.
The observation that the Alzheimer’s disease brain has a 
much-reduced capillary and vascular network has led to the 
formulation of the vascular hypothesis. There is much evi-
dence linking the brain’s vascular network and the disease. 
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Research has found that hypertension and diabetes, which 
both have vascular effects, significantly increase the risk 
of the development of the disease (Prince et al., 2014). In 
one study, it was discovered that the formation of 85% of 
the amyloid plaques in AD brains were either centered or 
proximal to vasculature (Kumar & Singh et al., 2005). A 
study of several different forms of dementia including AD 
revealed substantial reductions in microvasculature (Buee 
et al., 1994). Although there appears to be a credible link 
between the disease and the vasculature, it is not entirely 
clear if AD causes damage to the vasculature or if a vascular 
insufficiency promotes deposition of Aβ plaque (Karran & 
De Strooper, 2016). 
One final hypothesis to consider is the Aβ oligomer hypoth-
esis (AβOH). This theory is a variation of the original ACH. 
The main traction behind this theory is that it provides pos-
sible explanation as to why the density and amount of am-
yloid plaques does not correlate with the symptoms of AD. 
According to the AβOH the oligomers act at a distance from 
the plaques and mediate their effects. There is a large amount 
of data in support of this view. These include the treatment of 
cells with Aβ oligomers to induce neuronal death, the impact 
of the oligomers on insulin and nicotinic receptors, and the 
injection of these oligomers in rat brains which induced im-
paired memory and cognition. The AβOH would also explain 
why amyloidocentric drugs have had little success (Karran & 
De Strooper, 2016). 
The cholinergic hypothesis and the amyloid cascade hypothe-
sis clearly are supported by the strongest evidence. The ear-
liest experiments demonstrating the reduction in cholinergic 
function provided the basis for much of the later research 
into Alzheimer’s disease. Studies have consistently shown 
reductions in the levels of enzymes responsible for acetyl-
choline synthesis, and loss of receptor activity disrupting its 
uptake into neurons. This together with the degeneration 
of cholinergic neurons has provided the basis for this hy-
pothesis. The genetic studies into familial Alzheimer’s disease 
and the link between the disease and Down’s syndrome laid 
the path for the formulation of the ACH which is the most 
comprehensive hypothesis in Alzheimer’s disease. The cho-
linergic hypothesis fails to explain the mutations in APP in 
familial Alzheimer’s disease, the formation of the Aβ peptide, 
amyloid plaques and neurofibrillary tangles. The Amyloid cas-
cade hypothesis too has its inconsistencies and unanswered 
questions. However, rather than rejecting the undeniable data 
in support of each of these hypothesis, understanding the 
links and interactions between the two may provide a clearer 
picture of the mechanism of disease and provide a target for 
more effective therapy.
The connection between the cholinergic system and APP 
processing has been established. In one study, human em-
bryonic kidney (HEK) cell lines were transfected with mus-
carinic acetylcholine receptors. As mentioned earlier there 
are five isoforms of muscarinic receptors; M1, M2, M3, M4 
and M5. Cells transfected with M1 and M3 receptors showed 
significant increase in the release of APPα the product in the 
non-amyloidogenic pathway, when exposed to Carbachol a 
muscarinic receptor agonist. These cells also released lower 
levels of Aβ (Nitsch et al., 1992). Similar effects were seen in 
rat cerebral cortex slices that were exposed to M1 receptor 
agonists (Pittel et al., 1996). In addition to the effect the cho-
linergic system has on APP processing, Aβ peptides appear 
to modulate cholinergic function. Picomolar and nanomolar 
concentration of the beta amyloid peptide inhibit acetyl-
choline release from neurons in studies conducted on rat 
hippocampus and cortex sections. The exact mechanism by 
which the Aβ adversely effects acetylcholine release remains 
unclear. However, it appears that the Aβ peptides inhibit up-
take of choline in the presynaptic neurons. The activity of 
choline acetyltransferase (ChAT) appears to be unaffected, 
while high affinity choline uptake is decreased by 20 minutes 
after incubation with Aβ (Kar et al., 2004). Further studies on 
rat septal neurons found that Aβ42 reduces the levels of ace-
tylcholine by inhibiting the activity of the enzyme pyruvate 
dehydrogenase (PDH). The inhibition of pyruvate dehydroge-
nase results in a reduction in the biosynthesis of Acetyl-CoA, 
which is critical for acetylcholine synthesis. Aβ peptides have 
also been shown to disrupt cellular signaling and secondary 
messengers activated by muscarinic receptors. 
Aside from the disruption to the various cellular process-
es Aβ exposure is also toxic to neurons in the long term. 
Differentiated cholinergic cell lines were the most suscepti-
ble to the toxic effects of beta amyloid, while GABAergic and 
serotonergic cells were more resistant. As stated above Aβ 
peptide appears to effect choline uptake in neurons. Under 
conditions of choline depletion, cells synthesize acetylcho-
line using membrane phosphatidylcholine. Therefore, a severe 
choline depletion may result in regulated membrane turn-
over being disrupted and eventually lead to cell death. 
Aβ has also been shown to have a role in the hyper-phosphor-
ylation of Tau. Hyper- phosphorylated Tau can no longer asso-
ciate with microtubules, effecting both cell structure and vital 
mechanisms of transport. In cholinergic cell lines, aggregated 
Aβ peptide induced the phosphorylation of Tau proteins. The 
exact mechanism is unclear but it is most likely a result of an 
increase in kinase activity as Aβ peptides have been shown to 
increase the activity of both MAP kinase and GSK3β. 
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Conclusion
With the wealth of evidence in support of both the cholinergic 
hypothesis and the amyloid cascade hypothesis, an attempt at 
fully understanding the mechanism of disease will require better 
understanding of the link between Aβ peptides and the cholin-
ergic system. The cholinergic system has been shown to play a 
significant role in the regulation of APP processing. Reciprocally, 
studies have found that the accumulation of Aβ peptides disrupts 
the muscarinic and nicotinic receptors on cholinergic neurons 
while also having a downstream effect on the signaling pathway 
and secondary messengers. In addition, Aβ inhibits synthesis 
of acetylcholine in a variety of ways and cholinergic neurons 
are particularly susceptible to the toxic effects of Aβ peptide. 
Genetics provides the basis of support for the amyloid cascade 
hypothesis, and while the amyloid plaque density may not cor-
relate well with cognitive impairment in Alzheimer’s disease, its 
interactions with the cholinergic system may be responsible for 
the symptoms of AD. The exact mechanism of that interaction 
needs to be better elucidated, as that understanding provides 
the greatest potential for more effective and targeted therapy.
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